Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the official launch of its Lacosamide Injection USP, 200mg/mL,20mg/mL, 10mg/mL available in Single-Dose Vials, as detailed in the official announcement.
Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat® Injection (200mg/mL,20mg/mL}) of UCB, Inc. . According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market achieved annual sales of approximately $15.2 million.
“The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States,” said Marc Kikuchi, President & Business Head, North America. “By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.”
Glenmark’s Lacosamide Injection USP is approved specifically for the indication(s) listed in Glenmark’s approved product label.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
